Prevention of central sensitization and pain by N-methyl-D-aspartate receptor antagonists

Journal of the American Veterinary Medical Association

Volumn 228, Issue 1, 2006, Pages 53-60

  Pozzi, Antonio ^a   Muir III, William W ^a   Traverso, Francesca ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; AMANTADINE; AMPA RECEPTOR; BRADYKININ; CALCIUM ION; CYTOKINE; DEXTROMETHORPHAN; GABAPENTIN; GLUTAMIC ACID; KAINIC ACID RECEPTOR; KETAMINE; MAGNESIUM ION; MEMANTINE; METHADONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NEUROPEPTIDE; PROSTAGLANDIN; TELAZOL; TILETAMINE; TRAMADOL; ZOLAZEPAM;

ALLODYNIA; ANESTHESIA; CHRONIC PAIN; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERALGESIA; HYPERSALIVATION; HYPERTENSION; KIDNEY DYSFUNCTION; MUSCLE RIGIDITY; NAUSEA; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE RECEPTOR; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN; POSTOPERATIVE PAIN; RESPIRATION DEPRESSION; RESPIRATORY DISTRESS; REVIEW; SEDATION; SEIZURE; SENSITIZATION; TACHYCARDIA; TISSUE INJURY; VOMITING;

ANALGESICS; ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; PAIN; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 29844444181     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.228.1.53     Document Type: Review

References (123)

1. Meranda C, Di Virgilio M, Selleri S, et al. Novel pathogenic mechanism of congenital insensitivity to pain with anhidrosis genetic disorders unveiled by functional analysis of neurotropic tyrosine receptor kinase type 1/nerve growth factor mutations. J Biol Chem 2002;277:6455-6462.
2. Craig AD. Interoception: the sense of the physiological condition of the body. Curr Opin Neurobiol 2003;13:500-505.
3. Muir WW III, Woolf CJ. Mechanisms of pain and their therapeutic implications. J Am Vet Med Assoc 2001;219:1346-1356.
4. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000;288:1765-1769.
5. Petrenko AB, Yamakura T, Baba H, et al. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003;97:1108-1116.
6. Woolf CJ. Pain: moving from symptom control towards mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-451.
7. Pogatzki EM, Niemeier JS, Sorkin LS, et al. Spinal glutamate receptor antagonists differentiate primary and secondary mechanical hyperalgesia caused by incision. Pain 2003;105:97-107.
8. Kawamata M, Watanabe H, Nishikawa K, et al. Different mechanisms of development and maintenance of experimental incision-induced hyperalgesia in human skin. Anesthesiology 2002;97:550-559.
9. Baranauskas G, Nistri A. Sensitization of pain pathways in the spinal cord: cellular mechanism. Prog Neurobiol 1998;54:349-365.
10. Carroll RC, Zukin RS. NMDA-receptor trafficking and targeting: implications for synaptic transmission and plasticity. Trends Pharmacol Sci 2002;25:571-577.
11. Ji RR, Kohno T, Moore KA, et al. Central sensitization and LPT: do pain and memory share similar mechanism? Trends Neurosci 2003;26:696-705.
12. Pogatzki EM, Vandermeulen EP, Brennan TJ. Effect of plantar local anesthetic injection on dorsal horn neuron activity and pain behaviors caused by incision. Pain 2002;97:151-161.
13. Siddall PJ, Cousins MJ. Persistent pain as a disease entity: implications for clinical management. Anesth Analg 2004;99:510-520.
14. Nagy J. Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism? IDrugs 2004;7:339-350.
15. Li J, McRoberts JA, Nie J, et al. Electrophysiological characterization of N-methyl-D-aspartate receptors in rat dorsal root ganglia neurons. Pain 2004;109:443-452.
16. Kakinohana M, Kakinohana O, Jun JH, et al. The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia. Anesth Analg 2005;100:327-334.
17. Olivar T, Laird JMA. Differential effects of N-methyl-D-aspartate receptor blockade on nociceptive somatic and visceral reflexes. Pain 1999;79:67-73.
18. Willert RP, Woolf CJ, Hobson AR, et al. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D- aspartate. Gastroenterology 2004;126:683-692.
19. Ossipov MH, Lai J, King T, et al. Antinociceptive and nociceptive actions of opioids. J Neurobiol 2004;61:126-148.
20. Chizh BA, Headley PM, Tzschentke TM. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci 2001;22:636-641.
21. McCartney CJL, Sinha A, Katz J. A qualitative systematic review of the role of N-methyl-D-aspartate receptor antagonists in preventive analgesia. Anesth Analg 2004;98:1385-1400.
22. Ilkjaer S, Petersen KI, Brennum J, et al. Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans. Br J Anaesth 1996;76:829-834.
23. Callahan RJ, Au JD, Paul M, et al. Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in xenopus oocytes: stereospecific and subunit effects. Anesth Analg 2004;98:653-659.
24. 2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 1992;356:521-523.
25. Brenner GJ, Ji RR, Shaffer S, et al. Peripheral noxious stimulation induces phosphorylation of the NMDA receptor NR1 subunit at the PKC-dependent site, serine-896, in spinal cord dorsal horn neurons. Eur J Neurosci 2004;20:375-384.
26. Guo W, Zou S, Guan Y, et al. Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia. J Neurosci 2002;22:6208-6217.
27. Petrenko AB, Yamakura T, Baba H, et al. Unaltered pain-related behavior in mice lacking NMDA receptor GluRepsilon 1 subunit. Neurosci Res 2003;46:199-204.
28. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360-1362.
29. Eisenach JC. Preemptive hyperalgesia, not analgesia? Anesthesiology 2000;92:308-309.
30. Bowen JM, Blackmon DM, Heavner JE. Neuromuscular transmission and hypocalcemic paresis in the cow. Am J Vet Res 1970;31:831-839.
31. Sobow T. The clinical relevance of memantine use [in Polish]. Psychiatr Pol 2004;38:321-330.
32. Wiech K, Kiefer RT, Topfner S, et al. A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth Analg 2004;98:408-413.
33. Lin HC, Thurmon JC, Benson GJ, et al. Telazol: a review of its pharmacology and use in veterinary medicine. J Vet Pharmacol Ther 1993;16:383-418.
34. Amarpal GR, Aithal HP, Singh GR, et al. Pre-emptive effects of epidural ketamine for analgesia in dogs. Indian Vet J 1999;76:300-302.
35. Wagner AE, Walton JA, Hellyer PW, et al. Use of low doses of ketamine administered by constant rate infusion as an adjunct for postoperative analgesia in dogs. J Am Vet Med Assoc 2002;221:72-75.
36. Jones RS. Epidural analgesia in the dog and cat. Vet J 2001;161:123-131.
37. Martin DD, Tranquilli WJ, Olson WA, et al. Hemodynamic effects of epidural ketamine in isoflurane-anesthetized dogs. Vet Surg 1997;26:505-509.
38. Muir WW III, Wiese AJ, March PA. Effects of morphine, lidocaine, ketamine and morphine-lidocaine-ketamine drug combination on minimum alveolar concentration in dogs anesthetized with isoflurane. Am J Vet Res 2003;64:1155-1160.
39. Schwieger IM, Szlam F, Hug CC Jr. The pharmacokinetics and pharmacodynamics of ketamine in dogs anesthetized with enflurane. J Pharmacokinet Biopharm 1991;19:145-156.
40. Joubert K. Ketamine hydrochloride-an adjunct for analgesia in dogs with burn wounds. J S Afr Vet Assoc 1998;69:95-97.
41. Slingsby LS, Waterman-Pearson AE. The post-operative analgesic effects of ketamine after canine ovariohysterectomy: a comparison between pre- or post-operative administration. Res Vet Sci 2000;69:147-152.
42. Woolf CJ, Chong MS. Preemptive analgesia-treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 1993;77:362-379.
43. Woolf CJ, Max MB. Mechanism-based pain diagnosis. Anesthesiology 2001;95:241-249.
44. Zahn PK, Pogatzki-Zahn EM, Brennan TJ. Spinal administration of MK-801 and NBQX demonstrates NMDA-independent dorsal horn sensitization in incisional pain. Pain 2005;114:499-510.
45. De Kock M, Lavand'homme P, Waterloos H. 'Balanced analgesia' in the perioperative period: is there a place for ketamine? Pain 2001;92:373-380.
46. Grant IS, Nimmo WS, Clements JA. Lack of effect of ketamine analgesia on gastric emptying in man. Br J Anaesth 1981;53:1321-1323.
47. Amarpal GR, Aithal HP, Kinjavdekar P, et al. Interaction between epidurally administered ketamine and pethidine in dogs. J Vet Med 2003;50:254-258.
48. Dal D, Tetik O, Altunkaya H, et al. The efficacy of intraarticular ketamine for postoperative analgesia in outpatient arthroscopic surgery. Arthroscopy 2004;20:300-305.
49. Redua MA, Valadao CAA, Duque JC, et al. The pre-emptive effect of epidural ketamine on wound sensitivity in horses tested by using von-Frey filaments. Vet Anesth Analg 2002;29:200-206.
50. Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999;82:111-125.
51. Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anesth 1996;77:441-444.
52. Scheller M, Bufler J, Hertle I, et al. Ketamine blocks currents through mammalian nicotinic acetylcholine receptor channels by interaction with both the open and the closed state. Anesth Analg 1996;83:830-836.
53. Smith DJ, Pekoe GM, Martin LL, et al. The interaction of ketamine with the opiate receptor. Life Sci 1980;26:789-795.
54. Willetts J, Balster RL, Leander JD. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 1990;11:423-428.
55. Stubhaug A, Breivik H, Eide PK, et al. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiol Scand 1997;41:1124-1132.
56. Schwinn DA, Leslie JB, Watkins WD. Basic principles of pharmacology and anesthesia. In: Miller RD, ed. Anesthesia, 1. New York: Churchill Livingstone Inc, 1994;43-66.
57. Enarson MC, Hays H, Woodroffe MA. Clinical experience with oral ketamine. J Pain Symptom Manage 1999;17:384-386.
58. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence based review. Anesth Analg 2003;97:1730-1739.
59. Weinbroum AA, Ben-Abraham R. Dextromethorphan and dexmedetomidine: new agents for the control of perioperative pain. Eur J Surg 2001;167:563-569.
60. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995;187:165-168.
61. Ebert B, Thorkildsen C, Andersen S, et al. Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Biochem Pharmacol 1998;56:553-559.
62. Manfredi PL, Foley KM, Payne R, et al. Parenteral methadone: an essential medication for the treatment of pain. J Pain Symptom Manage 2003;26:687-688.
63. Manfredi PL, Gonzales GR, Cheville AL, et al. Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy. J Pain Symptom Manage 2001;21:169-174.
64. Mercadante S. Methadone in cancer pain. Eur J Pain 1997;1:77-85.
65. McDonnell FJ, Sloan JW, Hamann SR. Advances in cancer pain management. Curr Oncol Rep 2000;2:351-357.
66. Scott LJ, Perry CM. Tramadol: a review of its use in perioperative pain. Drugs 2000;60:139-176.
67. Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999;83:85-90.
68. Hara K, Minami K, Sata T. The effects of tramadol and its metabolite on glycine, gamma-aminobutyric acid, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Anesth Analg 2005;100:1400-1405, table of contents.
69. Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage: 2000;19(suppl 1):S21-S25.
70. Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233-249.
71. Serpell MG, Neuropatic Pain Study Group. Gabapentin in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Pain 2002;99:557-566.
72. Maneuf YP, Gonzalez MI, Sutton KS, et al. Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci 2003;60:742-750.
73. Gottrup H, Juhl G, Kristensen AD, et al. Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia. Anesthesiology 2004;101:1400-1408.
74. Gu Y, Huang LY. Gabapentin actions on N-methyl-D-aspartate receptor channels are protein kinase C-dependent. Pain 2001;93:85-92.
75. Dirks J, Petersen KL, Rowbotham MC, et al. Gabapentin suppresses cutaneous hyperalgesia following heat-capsaicin sensitization. Anesthesiology 2002;97:102-107.
76. Harding LM, Kristensen JD, Baranowski AP. Differential effects of neuropathic analgesics on wind-up-like pain and somatosensory function in healthy volunteers. Clin J Pain 2005;21:127-132.
77. Gilron I, Orr E, Tu D, et al. A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement evoked pain after abdominal hysterectomy. Pain 2005;113:191-200.
78. Suarez LM, Suarez F, Del Olmo N, et al. Presynaptic NMDA autoreceptors facilitate axon excitability: a new molecular target for the anticonvulsant gabapentin. Eur J Neurosci 2005;21:197-209.
79. Dirks J, Fredensborg BB, Christensen D, et al. A randomized study of the effects of single-dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy. Anesthesiology 2002;97:560-564.
80. Fassoulaki A, Patris K, Sarantopoulos C, et al. The analgesic effect of gabapentin and mexiletine after breast surgery for cancer. Anesth Analg 2002;95:985-991.
81. Turan A, Karamanlioglu B, Memis D, et al. Analgesic effects of gabapentin after spinal surgery. Anesthesiology 2004;100:935-938.
82. Turan A, Karamanlioglu B, Memis D, et al. The analgesic effects of gabapentin after total abdominal hysterectomy. Anesth Analg 2004;98:1370-1373.
83. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41:261-309.
84. Vernier VG, Harmon JB, Stump JM, et al. The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol Appl Pharmacol 1969;15:642-665.
85. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2001;2:241-271.
86. Bouza C, Magro A, Munoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004;99:811-828.
87. Wesemann W, Sontag KH, Maj J. Pharmacodynamics and pharmacokinetics of memantine. Arzneimittelforschung 1983;33:1122-1134.
88. Snijdelaar DG, Koren G, Katz J. Effects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy: results of a preliminary study. Anesthesiology 2004;100:134-141
89. Fukui S, Komoda Y, Nosaka S. Clinical application of amantadine, an NMDA antagonist, for neuropathic pain. J Anesth 2001;15:179-181.
90. Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 2000;20:358-373.
91. Zhang GH, Min SS, Lee KS, et al. Intraarticular pretreatment with ketamine and memantine could prevent arthritic pain: relevance to the decrease of spinal c-fos expression in rats. Anesth Analg 2004;99:152-158.
92. Maier C, Dertwinkel R, Mansourian N, et al. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain: results of a randomized double-blinded, placebo-controlled trial. Pain 2003;103:277-283.
93. Pud D, Eisenberg E, Spitzer A, et al. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 1998;75:349-354.
94. Amin P, Sturrock ND. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabet Med 2003;20:114-118.
95. Berrino L, Oliva P, Massimo F, et al. Antinociceptive effect in mice of intraperitoneal N-methyl-D-aspartate receptor antagonists in the formalin test. Eur J Pain 2003;7:131-137.
96. Eide PK, Stubhaug A, Oye I, et al. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 1995;61:221-228.
97. Dich-Nielsen JO, Svendsen LB, Berthelsen P. Intramuscular low-dose ketamine versus pethidine for postoperative pain treatment after thoracic surgery. Acta Anaesthesiol Scand 1992;36:538-587.
98. Bhattacharya A, Gurnani A, Sharma PK, et al. Subcutaneous infusion of ketamine and morphine for relief of postoperative pain: a double-blind comparative study. Ann Acad Med Singapore 1994;23:456-459.
99. Silvasti M, Karttunen P, Happonen P, et al. Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. Int J Clin Pharmacol Ther Toxicol 1990;28:268-272.
100. Katz J. Pre-emptive analgesia: evidence, current status and future directions. Eur J Anaesthesiol Suppl 1995;10:8-13.
101. Moiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology 2002;96:725-741.
102. Woolf CJ. Somatic pain pathogenesis and prevention. Br J Anaesth 1995;75:169-176.
103. Fu ES, Miguel R, Scharf JE. Preemptive ketamine decreases postoperative narcotic requirements in patients undergoing abdominal surgery. Anesth Analg 1997;84:1086-1090.
104. Eisenach JC. Preemptive hyperalgesia, not analgesia? Anesthesiology 2000;92:308-309.
105. Lamont LA, Tranquilli WJ, Grimm KA. Physiology of pain. Vet Clin North Am Small Anim Pract 2000;30:703-728.
106. Schulte H, Sollevi A, Segerdahl M. The synergistic effect of combined treatment with systemic ketamine and morphine on experimentally induced windup like pain in humans. Anesth Analg 2004;98:1574-1580.
107. Bossard AE, Guirimand F, Fletcher D, et al. Interaction of a combination of morphine and ketamine on the nociceptive flexion reflex in human volunteers. Pain 2002;98:47-57.
108. Menigaux C, Guignard B, Fletcher D, et al. Intraoperative small dose ketamine enhances analgesia after outpatient knee arthroscopy. Anesth Analg 2001;93:606-612.
109. Lauretti GR, Lima IC, Reis MP, et al. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999;90:1528-1533.
110. Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999;82:111-125.
111. Nemmani KVS, Grisel JE, Stowe J, et al. Modulation of morphine analgesia by site specific N-methyl-D-aspartate receptor antagonists: dependence on sex, site of antagonism, morphine dose, and time. Pain 2004;109:274-283.
112. Chia YY, Liu K, Liu YC, et al. Adding ketamine in a multimodal patient-controlled epidural regimen reduces postoperative pain and analgesic consumption. Anesth Analg 1998;86:1245-1249.
113. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004;99:482-495.
114. Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes? Drugs 1998;55:1-4.
115. Heiskanen T, Hartel B, Dahl ML, et al. Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain 2002;96:261-267.
116. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995;62:259-274.
117. Kissin I, Bright CA, Bradley EL Jr. The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations? Anesth Analg 2000;91:1483-1488.
118. Kochs E, Scharein E, Möllenberg O, et al. Analgesic efficacy of low dose ketamine. Somatosensory evoked responses in relation to subjective pain ratings. Anesthesiology 1996;85:304-314.
119. Lees P, Landoni MF, Giraudel J, et al. Pharmacodynamics and pharmacokinetics of nonsteroidal anti inflammatory drugs in species of veterinary interest. J Vet Pharmacol Ther 2004;27:479-490.
120. Herrero JF, Headley PM. Reversal by naloxone of the spinal antinociceptive actions of a systemically administered NSAID. Br J Pharmacol 1996;118:968-972.
121. Lees P, Landoni MF, Giraudel J, et al. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. J Vet Pharmacol Ther 2004;27:479-490.
122. Kelly DJ, Ahmad M, Brull SJ. Preemptive analgesia 1: physiological pathways and pharmacological modalities. Can J Anaesth 2001;48:1000-1010.
123. Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med 2002;8:390-396.